Antifibrotic Research
B7-33
Not yet scored
BioHarmony verdict
Awaiting review
No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.
What is B7-33?
B7-33 is a preclinical single-chain relaxin-family peptide agonist studied for selective antifibrotic signaling in animal models. Human safety and effectiveness have not been established.
Dosing as published
No approved-label or study protocol is recorded for B7-33 yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
US approvalInvestigational
CompoundingEligibility not established.
Last checked2026-07-13
Next review2027-01-09
Primary sources
- A single-chain derivative of the relaxin hormone is a functionally selective agonist of RXFP1PubMed / Science Translational Medicine · 2018-08-29
Related peptides for longevity & cellular
Free guide
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.